RE:RE:Pfizer & BioNTech partnership
Infinity wrote: Agree, a joint venture is the best case scenario. There is no way that Biontech could have acheived worldwide marketing of their vaccine without Pfizer, not a chance..
However, to establish a really good joint venture, you need to have
1. Excellent Clinical Test results. Peer reviews of other Urological Oncologists who specialise in Blader cancer treatment.
2. The share price has to move closer to the $ 5.00 mark to establish a joint venture that is favourable to the Share holders.
3. To achieve this goal, we need to have TLT listed in TSX, Nasdaq, or NYSE. To be listed in the larger exchanges the share price and market cap has to move up....
4. Everything hinges on the Clinical Test results and obtaining Break through Designation,,,
I truly believe, we are close to achieving this Goal and RDW is biding his time so that we can all get a joint venture under favourable terms.
When it comes to time frame, my guess is that we are still 1 to 2 years away from a joint venture. We will very likely have good results from the Vaccine side and that should ease the cash flow requirments to last the 2 years time frame.
In the mean time, if we have someone really talented leading the device marketing team for the Laser, we should be able to achieve the goals sooner....TLT may even spin off the Laser division completely to concentrate on the Anti cancer and the Vaccine research..
Any which way you look at it, TLT is poised to grow and take off within the next two years time...IMO
Agree....a JV would be ideal, & not until we are FDA approved for this indication, on a real exchange & preferably sitting at least in the $5-10 range. The real question is, how do we reasonably get there?
A BTD is a significant milestone achievement. Though on this exchange, I expect it would lead to one small step-up in share price, yet one giant leap away from a worthwhile up listing (Nasdaq, etc.) imo. Remaining parked on this exchange until drug approval may be the best option...more shares to accumulate, which works for me.